Advisor Partners’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $2.12M | Buy |
25,112
+2,078
| +9% | +$182K | 0.15% | 139 |
|
|
2022
Q1 | $2.02M | Buy |
23,034
+2,933
| +15% | +$254K | 0.13% | 160 |
|
|
2021
Q4 | $1.76M | Sell |
20,101
-1,360
| -6% | -$113K | 0.11% | 187 |
|
|
2021
Q3 | $1.75M | Sell |
21,461
-3,180
| -13% | -$286K | 0.12% | 170 |
|
|
2021
Q2 | $2.25M | Buy |
24,641
+632
| +3% | +$56.3K | 0.15% | 134 |
|
|
2021
Q1 | $2.05M | Sell |
24,009
-695
| -3% | -$62.4K | 0.15% | 140 |
|
|
2020
Q4 | $2.33M | Sell |
24,704
-3,112
| -11% | -$272K | 0.18% | 112 |
|
|
2020
Q3 | $2.42M | Buy |
27,816
+1,964
| +8% | +$170K | 0.21% | 92 |
|
|
2020
Q2 | $2.26M | Buy |
25,852
+7,621
| +42% | +$658K | 0.21% | 94 |
|
|
2020
Q1 | $1.5M | Sell |
18,231
-2,535
| -12% | -$226K | 0.18% | 120 |
|
|
2019
Q4 | $1.96M | Buy |
20,766
+727
| +4% | +$65.2K | 0.2% | 112 |
|
|
2019
Q3 | $1.74M | Buy |
20,039
+567
| +3% | +$50.9K | 0.21% | 106 |
|
|
2019
Q2 | $1.78M | Sell |
19,472
-1,069
| -5% | -$90.5K | 0.22% | 90 |
|
|
2019
Q1 | $1.77M | Sell |
20,541
-1,049
| -5% | -$84.2K | 0.23% | 85 |
|
|
2018
Q4 | $1.66M | Buy |
21,590
+6,270
| +41% | +$488K | 0.27% | 81 |
|
|
2018
Q3 | $1.18M | Buy |
15,320
+4,253
| +38% | +$314K | 0.16% | 125 |
|
|
2018
Q2 | $749K | Buy |
11,067
+252
| +2% | +$17.4K | 0.13% | 188 |
|
|
2018
Q1 | $784K | Buy |
10,815
+2,049
| +23% | +$156K | 0.15% | 167 |
|
|
2017
Q4 | $683K | Buy |
8,766
+3,127
| +55% | +$236K | 0.12% | 194 |
|
|
2017
Q3 | $434K | Buy |
5,639
+1,677
| +42% | +$127K | 0.09% | 263 |
|
|
2017
Q2 | $296K | Buy |
3,962
+493
| +14% | +$34.9K | 0.07% | 338 |
|
|
2017
Q1 | $231K | Sell |
3,469
-2,619
| -43% | -$175K | 0.06% | 382 |
|
|
2016
Q4 | $397K | Buy |
6,088
+1,231
| +25% | +$79.9K | 0.12% | 205 |
|
|
2016
Q3 | $344K | Buy |
4,857
+1,368
| +39% | +$99.7K | 0.11% | 210 |
|
|
2016
Q2 | $258K | Buy |
3,489
+352
| +11% | +$24.3K | 0.09% | 269 |
|
|
2016
Q1 | $204K | Sell |
3,137
-6,314
| -67% | -$430K | 0.08% | 319 |
|
|
2015
Q4 | $729K | Buy |
9,451
+190
| +2% | +$15.1K | 0.25% | 113 |
|
|
2015
Q3 | $763K | Sell |
9,261
-108
| -1% | -$9.61K | 0.32% | 85 |
|
|
2015
Q2 | $826K | Buy |
9,369
+1,174
| +14% | +$108K | 0.32% | 92 |
|
|
2015
Q1 | $724K | Sell |
8,195
-1,106
| -12% | -$98.1K | 0.31% | 94 |
|
|
2014
Q4 | $772K | Sell |
9,301
-24
| -0.3% | -$1.99K | 0.34% | 94 |
|
|
2014
Q3 | $787K | Buy |
9,325
+96
| +1% | +$7.77K | 0.45% | 69 |
|
|
2014
Q2 | $749K | Buy |
9,229
+13
| +0.1% | +$1.02K | 0.37% | 80 |
|
|
2014
Q1 | $702K | Sell |
9,216
-222
| -2% | -$16.2K | 0.39% | 75 |
|
|
2013
Q4 | $680K | Buy |
9,438
+1,060
| +13% | +$73.7K | 0.39% | 80 |
|
|
2013
Q3 | $576K | Buy |
8,378
+489
| +6% | +$32.4K | 0.41% | 82 |
|
|
2013
Q2 | $500K | Buy |
+7,889
| New | +$513K | 0.41% | 80 |
|
Other funds holding NVS
Advisor Partners's NVS Position: Q2 2022 in Review
Advisor Partners increased its Novartis (NVS) stake by 9% in Q2 2022, buying an estimated $182K and bringing the position to 25,112 shares worth $2.12M. The position accounts for 0.15% of the portfolio, ranked #139.
Advisor Partners first reported a position in NVS in Q2 2013 and has held it in 37 quarters since. The position peaked at $2.42M in Q3 2020. 1,141 funds tracked by Wall St. Rank hold NVS as of Q2 2022.
- Advisor Partners held 25,112 shares of Novartis worth $2.12M as of Q2 2022.
- Advisor Partners bought 2,078 Novartis shares in Q2 2022, an estimated $182K.
- Novartis made up 0.15% of Advisor Partners's portfolio in Q2 2022, its #139 holding.
- Advisor Partners first reported a position in Novartis in Q2 2013 and has held it in 37 quarters since.
- Advisor Partners's Novartis position peaked at $2.42M in Q3 2020.
- 1,141 funds tracked by Wall St. Rank held Novartis as of Q2 2022.
Based on Advisor Partners's 13F filing for Q2 2022, filed 11 Aug 2022.